The Cancer Letter

The leading source for information on the issues that shape oncology since 1973

Guest Editorial

Thank you, Jim Allison

Share on facebook
Share on twitter
Share on linkedin
Share on email
Share on print
BYLINE
IN THIS ISSUE
BYLINEDOWNLOAD PDFTABLE OF CONTENTS

The year was 1998, location, Italian Alps. Jim and I were attending an intimate Pezcoller meeting organized by David Livingston. At that meeting, Jim presented something I had never seen in the entirety of my career—the eradication of cancer in mice following treatment with an antibody designed to inhibit a T cell checkpoint mechanism.

To access this subscriber-only content please log in or subscribe.

If your institution has a site license, log in with IP-login or register for a sponsored account.*
*Not all site licenses are enrolled in sponsored accounts.

Login Subscribe
Byline
Ronald A. DePinho
Professor, past president, Harry Graves Burkhart III Distinguished University Chair, Department of Cancer Biology, MD Anderson Cancer Center
Table of Contents

YOU MAY BE INTERESTED IN

Guest Editorial

USPSTF doesn’t lean right or left—it’s about data, not politics

Multiple components of the healthcare and public health systems are currently under scrutiny. One of them is reportedly the U.S. Preventive Services Task Force (USPSTF: “Task Force”), established in 1984 and managed by the Agency for Healthcare Research and Quality.  It was created to maintain an ongoing evaluation of disease prevention and screening interventions that...

By Barnett Kramer
Byline
Ronald A. DePinho
Professor, past president, Harry Graves Burkhart III Distinguished University Chair, Department of Cancer Biology, MD Anderson Cancer Center
Table of Contents

Never miss an issue!

Get alerts for our award-winning coverage in your inbox.

Login

Site license subscribers:
Log in with your IP | Register a sponsored account